SCHEMBL483655

SCHEMBL483655

CC(=O)NCC(O)CN(C(=O)OCC(C)C)c1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.44
LMNA P02545 2/20 0.44
MAOA P21397 2/20 0.44
PTGS1 P23219 1/20 0.44
CALML3 P27482 1/20 0.44
SDHA P31040 1/20 0.44
NPC1 O15118 3/20 0.39
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LDHA P00338 1/20 0.37
LDHB P07195 1/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483665 0.91 LMNA (0.45) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL483912 0.88 MAOB (0.45) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL483670 0.88 NPC1 (0.41) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL18595769 0.86 LMNA (0.48) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL483886 0.86 LMNA (0.48) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL483861 0.84 MAPT (0.40) LMNANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL483873 0.84 NPC1 (0.43) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL483968 0.82 NPC1 (0.44) LMNANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL483955 0.82 MLYCD (0.45) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL483612 0.82 NPC1 (0.44) MAOBLMNAMAOAPTGS1CALML3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP claimed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP claimed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US claimed
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP disclosed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP disclosed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives OXA1L, AAAS, MLYCD MAOB 648/4885LMNA 1359/4885MAOA 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.